Lipoprotein apheresis involves the extracorporeal removal ... the procedure is widely accepted as first-line therapy for homozygous familial hypercholesterolemia and is increasingly used to ...

Haemonetics (HAE) announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, a manufacturer of filter ...

"We will be opening our factory line in Hangzhou, Zhejiang province," said Antoinette Gawin, president and CEO of Terumo ...

Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first ...

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a ...

But that one apheresis was as at this point in time ... It's very different looking than you would typically see for available second-line therapies. But I expect when CTOS when the data gets ...

Selling the assets to Italy’s GVS should help Haemonetics improve its revenue growth and profit margins, analysts said.

Alyx is designed to help optimize your bottom line with reduced labor and error related costs and the ability to increase collection of high value components.

Haemonetics (NYSE:HAE) announced today that it agreed to sell its whole blood assets to GVS S.p.A for $67.1 million.

Haemonetics' Blood Center business will continue to manufacture and provide customers with its full line of apheresis solutions for automated blood collection. These include devices and disposable ...

Kite, a Gilead Company , announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with ...